Brief: Daiichi Sankyo Concludes pCPA Letter Of Intent For Vanflyta®
28/05/2026 20:24
BRIEF-Daiichi Sankyo Concludes pCPA Letter Of Intent For Vanflyta® May 28 (Reuters) - Daiichi Sankyo Co Ltd 4568.T:
DAIICHI SANKYO CONCLUDES PCPA LETTER OF INTENT FOR VANFLYTA® IN NEWLY DIAGNOSED FLT3-ITD POSITIVE AML
Source text: ID:nCNWnKdtMa
Further company coverage: 4568.T
((((Reuters.Briefs@thomsonreuters.com));))
Recent news on Daiichi Sankyo Co
See all newsNotice Regarding Conclusion Of A Money Loan Agreement With Financial Covenants
Brief: Daiichi Sankyo - Won Approval To Market 'Vanflyta (Quizartinib)' In China For First-Line Treatment Of Flt3-Itd Mutation-Positive Acute Myeloid Leukemia
Brief: Daiichi Sankyo Concludes pCPA Letter Of Intent For Vanflyta®
Brief: AstraZeneca Says Datroway Approved In US For 1L Triple-Negative BC
Brief: EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy